"2 dose vaccination schedule" trang 1 - tải miễn phí từ tailieunhanh
Optimal biological dose: A systematic review in cancer phase I clinical trials

Optimal biological dose: A systematic review in cancer phase I clinical trials
10    30    1
Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/ extended-release hydrocodone bitartrate/ acetaminophen (MNK-155) under fed and fasted conditions: Two randomized open-label trials

Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/ extended-release hydrocodone bitartrate/ acetaminophen (MNK-155) under fed and fasted conditions: Two randomized open-label trials
10    92    0
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
13    35    1
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
11    93    0
The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
9    56    1
Effcacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial

Effcacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial
9    14    1
Ebook Clark's essential physics in imaging for radiographers: Part 2

Ebook Clark's essential physics in imaging for radiographers: Part 2
107    69    0
Ebook Top 300 pharmacy drug cards: Part 2

Ebook Top 300 pharmacy drug cards: Part 2
313    86    0
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer
10    74    0
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)
11    38    1
The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus

The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus
11    57    1
Immunomodulatory effects of intraoperative dexmedetomidine on T helper 1, T helper 2, T helper 17 and regulatory T cells cytokine levels and their balance: A prospective, randomised, double-blind, dose-response clinical stud

Immunomodulatory effects of intraoperative dexmedetomidine on T helper 1, T helper 2, T helper 17 and regulatory T cells cytokine levels and their balance: A prospective, randomised, double-blind, dose-response clinical stud
7    22    1
A phase IA dose-escalation study of PHI101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

A phase IA dose-escalation study of PHI101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer
7    31    3
Ebook Radiologic science for technologists (11th edition): Part 2

Ebook Radiologic science for technologists (11th edition): Part 2
334    5    1
Ebook Medical mathematics and dosage calculations for veterinary technicians (3/E): Part 2

Ebook Medical mathematics and dosage calculations for veterinary technicians (3/E): Part 2
114    1    1
Ebook A guide to sample size for animal-based studies: Part 2

Ebook A guide to sample size for animal-based studies: Part 2
154    1    1
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
11    70    1
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma
10    21    1